Paper40539416
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
Milà-Alomà M and 27 others. Ann Neurol, 2025. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks. Papers, record 40539416. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40539416
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| tau Proteins | Major topic |
| Alzheimer Disease | Major topic |
| Amyloid beta-Peptides | Major topic |
| Humans | |
| Male | |
| Female | |
| Positron-Emission Tomography | |
| Biomarkers | |
| Aged | |
| Aged, 80 and over | |
| Disease Progression | |
| Longitudinal Studies | |
| Middle Aged | |
| Peptide Fragments | |
| Neurofilament Proteins | |
| Glial Fibrillary Acidic Protein | |
| Time Factors |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| a public-private partnership managed by the Foundation for the National Institutes of Health | Biomarkers Consortium, Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project | PubMed | PubMed | ||
| U24 AG021886 | NIA NIH HHS | United States | U24AG021886 | PubMed and NIH | NIH RePORTER |
| R01 AG070941 | NIA NIH HHS | United States | R01AG070941 | PubMed and NIH | NIH RePORTER |
| R01AG070941 | NIA NIH HHS | United States | R01AG070941 | PubMed and NIH | NIH RePORTER |
| U19 AG024904 | NIA NIH HHS | United States | U19AG024904 | PubMed and NIH | NIH RePORTER |
| AARF-23-1141384 | Alzheimer's Association | United States | PubMed | PubMed |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 39574864 |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35907254 | Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. | JAMA Neurol | 2022 | https://conductscience.org/library/papers/35907254 | PubMed |
| 2 | 38491912 | Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. | Alzheimers Dement | 2024 | https://conductscience.org/library/papers/38491912 | PubMed |
| 3 | 34661615 | Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. | JAMA Neurol | 2021 | https://conductscience.org/library/papers/34661615 | PubMed |
| 4 | 39255800 | Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease. | Med | 2024 | https://conductscience.org/library/papers/39255800 | PubMed |
| 5 | 36087307 | Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. | Brain | 2023 | https://conductscience.org/library/papers/36087307 | PubMed |
| 6 | 38400792 | Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. | Ann Neurol | 2024 | https://conductscience.org/library/papers/38400792 | PubMed |
| 7 | 37248300 | Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease. | Nat Med | 2023 | https://conductscience.org/library/papers/37248300 | PubMed |
| 8 | 8232972 | The Clinical Dementia Rating (CDR): current version and scoring rules. | Neurology | 1993 | https://conductscience.org/library/papers/8232972 | PubMed |
| 9 | 34504028 | Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. | Neurology | 2021 | https://conductscience.org/library/papers/34504028 | PubMed |
| 10 | 31371569 | High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. | Neurology | 2019 | https://conductscience.org/library/papers/31371569 | PubMed |
| 11 | 36987840 | Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. | JAMA Neurol | 2023 | https://conductscience.org/library/papers/36987840 | PubMed |
| 12 | 37216632 | Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/37216632 | PubMed |
| 13 | 27931796 | The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. | Alzheimers Dement | 2017 | https://conductscience.org/library/papers/27931796 | PubMed |
| 14 | 34542571 | Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. | JAMA Neurol | 2021 | https://conductscience.org/library/papers/34542571 | PubMed |
| 15 | 26194311 | The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. | Alzheimers Dement | 2015 | https://conductscience.org/library/papers/26194311 | PubMed |
| 16 | 30304397 | Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. | Brain | 2018 | https://conductscience.org/library/papers/30304397 | PubMed |
| 17 | 30847382 | Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. | Alzheimers Dement (Amst) | 2019 | https://conductscience.org/library/papers/30847382 | PubMed |
| 18 | 35678397 | Alzheimer Disease. | Continuum (Minneap Minn) | 2022 | https://conductscience.org/library/papers/35678397 | PubMed |
| 19 | 35856240 | Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. | Brain | 2022 | https://conductscience.org/library/papers/35856240 | PubMed |
| 20 | 36508198 | Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. | JAMA Neurol | 2023 | https://conductscience.org/library/papers/36508198 | PubMed |
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923225 | Noninvasive diagnosis of Alzheimer's disease: a review of emerging biomarkers and multimodal approaches. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42923225 | PubMed |
| 42889489 | Comparison of brain-derived versus conventional pTau biomarkers in CSF and plasma for detecting Alzheimer's disease. | Brain Commun | 2026 | https://conductscience.org/library/papers/42889489 | PubMed |
| 42798750 | Real-world implementation of lecanemab in Alzheimer's disease: A Japanese cohort. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42798750 | PubMed |
| 42768846 | Do amyloid trajectories reach a ceiling? Evidence from iterative approximation and simulation. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42768846 | PubMed |
| 42719047 | Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42719047 | PubMed |
| 42683384 | From amyloid PET to plasma biomarkers: A multimodal imaging framework for early diagnosis and staging of Alzheimer's disease. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42683384 | PubMed |
| 42638803 | Neuroimaging Epicenters as Vulnerable Nodes in Plasma p-tau217/Aβ42-Positive Alzheimer's Disease. | Research (Wash D C) | 2026 | https://conductscience.org/library/papers/42638803 | PubMed |
| 42637536 | Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing. | J Neurol Neurosurg Psychiatry | 2026 | https://conductscience.org/library/papers/42637536 | PubMed |
| 42601919 | Amyloid-β modulates APOE ε4 effects on cognition but not on targeted structural or functional connectivity measures over 2 years in pre-dementia adults. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/42601919 | PubMed |
| 42597443 | Toward personalized medicine in AD/ADRD through genetic-exposome dementia risk assessments. | NPJ Dement | 2026 | https://conductscience.org/library/papers/42597443 | PubMed |
| 42535261 | Exploring longitudinal relationships among Alzheimer's disease biomarkers. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42535261 | PubMed |
| 42523318 | Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease. | bioRxiv | 2026 | https://conductscience.org/library/papers/42523318 | PubMed |
| 42477212 | Patient-Derived PSEN1 Cerebral Organoids Revealed Parallel Development of Amyloid-β Accumulation and Network Dysfunction. | Cell Mol Neurobiol | 2026 | https://conductscience.org/library/papers/42477212 | PubMed |
| 42425064 | Recent advances in Alzheimer's disease: From molecular mechanisms to therapeutic strategies. | Cell | 2026 | https://conductscience.org/library/papers/42425064 | PubMed |
| 42369495 | Multi-domain AD risk burden and plasma biomarkers in cognitively unimpaired adults. | medRxiv | 2026 | https://conductscience.org/library/papers/42369495 | PubMed |
| 42323462 | Plasma p-Tau217 and Aβ42/Aβ40 mediate the association between minimal depressive symptoms and cognitive impairment. | J Neurol | 2026 | https://conductscience.org/library/papers/42323462 | PubMed |
| 42309987 | Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42309987 | PubMed |
| 42145632 | Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains. | medRxiv | 2026 | https://conductscience.org/library/papers/42145632 | PubMed |
| 42021299 | Plasma biomarker trajectories across Alzheimer's clinical onset: a 17-year prospective study. | Alzheimers Res Ther | 2026 | https://conductscience.org/library/papers/42021299 | PubMed |
| 42010230 | Brain, benefit, or burden? Revisiting statins and cognitive function in older adults. | Geroscience | 2026 | https://conductscience.org/library/papers/42010230 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APP | 351 | PubTator's text mining | https://conductscience.org/library/genes/351 | NCBI Gene |
| GFAP | 2670 | PubTator's text mining | https://conductscience.org/library/genes/2670 | NCBI Gene |
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 | NCBI Gene |
| NEFL | 4747 | PubTator's text mining | https://conductscience.org/library/genes/4747 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40539416
GET https://conductscience.org/api/papers/v1/40539416/authors?page=2